|
62 Companies |
|
89 Products |
|
89 Products |
|
76 Mechanisms of Action |
|
2 Trials |
|
652 News |
|
| «12...234567891011121314» |
- Biomarker, Trial completion: Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm (clinicaltrials.gov) - Jan 19, 2014
P=N/A, N=1, Completed, Sponsor: Norman Eberhardt
Enrolling by invitation --> Completed
- sirolimus / Generic mfg.
Enrollment change, Metastases: Rapamycin With Grapefruit Juice for Advanced Malignancies (clinicaltrials.gov) - Jan 15, 2014
P1, N=41, Completed, Sponsor: University of Chicago
Enrolling by invitation --> Completed N=64 --> 41
- ketorolac / Generic mfg.
Surgery: The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery (clinicaltrials.gov) - Jan 15, 2014
P=N/A, N=120, Recruiting, Sponsor: Yeungnam University College of Medicine
- sirolimus / Generic mfg.
Trial completion, Metastases: Rapamycin With Grapefruit Juice for Advanced Malignancies (clinicaltrials.gov) - Jan 15, 2014
P1, N=41, Completed, Sponsor: University of Chicago
N=64 --> 41 Active, not recruiting --> Completed
- | Prolia (denosumab) / Amgen
Trial completion: Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium (clinicaltrials.gov) - Jan 12, 2014
P2, N=33, Completed, Sponsor: Amgen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial initiation date: Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=500, Recruiting, Sponsor: University Hospital, Rouen
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Sep 2012
- Enrollment open: Galectin 3 Dosage in Diagnosis of Nodular and Multinodular Goiter (clinicaltrials.gov) - Jan 5, 2014
P=N/A, N=500, Recruiting, Sponsor: University Hospital, Rouen
Initiation date: Jun 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- Enrollment change: Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=66, Completed, Sponsor: University of Sao Paulo
Not yet recruiting --> Recruiting N=100 --> 66
- Trial completion, Surgery: Open Thyroid Surgery With Pillow Versus no Pillow for Better Post-operative Outcomes (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=180, Completed, Sponsor: The University of Hong Kong
N=100 --> 66 Recruiting --> Completed
- Trial completion: Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy (clinicaltrials.gov) - Dec 17, 2013
P=N/A, N=66, Completed, Sponsor: University of Sao Paulo
Recruiting --> Completed Recruiting --> Completed
- | Trial completion, Enrollment change: Thyroid and Glucose and Energy Metabolism (clinicaltrials.gov) - Dec 9, 2013
P2, N=30, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed N=50 --> 30 | Recruiting --> Completed
- Trial completion: Thyroid and Glucose and Energy Metabolism (clinicaltrials.gov) - Dec 9, 2013
P2, N=30, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
N=50 --> 30 | Recruiting --> Completed Recruiting --> Completed
- Trial completion, Surgery: Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease (clinicaltrials.gov) - Dec 4, 2013
P=N/A, N=10, Completed, Sponsor: Sensimed AG
Recruiting --> Completed Recruiting --> Completed
- |||| thyroxine / Generic mfg.
Trial completion: Effects of L-carnitine on Hypothyroidism (clinicaltrials.gov) - Dec 1, 2013
P4, N=60, Completed, Sponsor: Korea University Anam Hospital
Recruiting --> Completed Recruiting --> Completed
- Trial withdrawal: Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism (clinicaltrials.gov) - Nov 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed Recruiting --> Withdrawn
- Enrollment change: Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism (clinicaltrials.gov) - Nov 29, 2013
P=N/A, N=0, Withdrawn, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Withdrawn N=20 --> 0
- Trial completion: Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study (clinicaltrials.gov) - Nov 24, 2013
P=N/A, N=1000, Completed, Sponsor: Peking Union Medical College Hospital
N=20 --> 0 Enrolling by invitation --> Completed
- Enrollment change: The Role of Elastography in the Diagnosis of Thyroid Nodules (clinicaltrials.gov) - Nov 21, 2013
P=N/A, N=187, Recruiting, Sponsor: Centre Hospitalier Universitaire de N?mes
Enrolling by invitation --> Completed N=140 --> 187
- doxycycline / Generic mfg.
Trial completion: Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy (clinicaltrials.gov) - Nov 20, 2013
P1/2, N=14, Completed, Sponsor: Sun Yat-sen University
N=140 --> 187 Recruiting --> Completed
- Clinical: 90‐Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=13, Completed, Sponsor: Cardno ChemRisk
- Enrollment change: Effects of THW and rhTSH in Glomerular Filtration Rate During RIT (clinicaltrials.gov) - Nov 18, 2013
P=N/A, N=26, Recruiting, Sponsor: University of Sao Paulo General Hospital
Recruiting --> Completed N=44 --> 26
- ||||| New P1/2 trial: Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients (clinicaltrials.gov) - Nov 18, 2013
P1/2, N=300, Not yet recruiting, Sponsor: Jewish General Hospital
- Trial completion: Morphometric Analysis of Orbital Structures in Graves (clinicaltrials.gov) - Nov 16, 2013
P=N/A, N=80, Completed, Sponsor: University of Sao Paulo
N=44 --> 26 Recruiting --> Completed
- Clinical: Iodine Supplementation in Obesity (clinicaltrials.gov) - Nov 13, 2013
P=N/A, N=160, Recruiting, Sponsor: Swiss Federal Institute of Technology
- thyroxine / Generic mfg.
Trial completion: Neurocognitive and Metabolic Effects of Mild Hypothyroidism (clinicaltrials.gov) - Nov 6, 2013
P=N/A, N=324, Completed, Sponsor: Oregon Health and Science University
Recruiting --> Completed Recruiting --> Completed
- Trial termination: Safety Study of CALAA-01 to Treat Solid Tumor Cancers (clinicaltrials.gov) - Oct 29, 2013
P1, N=24, Terminated, Sponsor: Calando Pharmaceuticals
Recruiting --> Completed Active, not recruiting --> Terminated
- Enrollment change: Safety Study of CALAA-01 to Treat Solid Tumor Cancers (clinicaltrials.gov) - Oct 29, 2013
P1, N=24, Terminated, Sponsor: Calando Pharmaceuticals
Active, not recruiting --> Terminated N=36 --> 24
- Istodax (romidepsin) / Astellas, BMS
Enrollment change, Metastases: Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine (clinicaltrials.gov) - Oct 28, 2013
P2, N=20, Completed, Sponsor: National Cancer Institute (NCI)
N=36 --> 24 N=41 --> 20
- || ZY T1 / Zydus Lifesci
Enrollment closed: A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers (clinicaltrials.gov) - Oct 24, 2013
P1, N=112, Active, not recruiting, Sponsor: Cadila Healthcare Limited
N=41 --> 20 Recruiting --> Active, not recruiting
- ||| melphalan / Generic mfg.
Enrollment change, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
Recruiting --> Active, not recruiting N=105 --> 56
- |||| melphalan / Generic mfg.
Trial completion, Metastases: Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov) - Oct 21, 2013
P2, N=56, Completed, Sponsor: Delcath Systems Inc.
N=105 --> 56 Active, not recruiting --> Completed
- ||| dovitinib (TKI258) / Novartis, Oncoheroes
Trial initiation date: SIGNATURE: Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib (clinicaltrials.gov) - Oct 20, 2013
P2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: May 2013 --> Aug 2013
- Enrollment open: IIFHT: Interrelations Between FT3, FT4 and Pituitary TSH (clinicaltrials.gov) - Oct 20, 2013
P=N/A, N=1600, Recruiting, Sponsor: Klinikum L
Initiation date: May 2013 --> Aug 2013 Not yet recruiting --> Recruiting
- |||| dovitinib (TKI258) / Novartis, Oncoheroes
Enrollment open: SIGNATURE: Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib (clinicaltrials.gov) - Oct 20, 2013
P2, N=70, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- dovitinib (TKI258) / Novartis, Oncoheroes
New P2 trial, Metastases: An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer (clinicaltrials.gov) - Oct 15, 2013
P2, N=40, Recruiting, Sponsor: Yonsei University
- Enrollment change: Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=81, Completed, Sponsor: Mount Sinai School of Medicine
Not yet recruiting --> Recruiting N=50 --> 81
- Trial completion: Hospital-Based Phthalate Exposure in Very Low Birth Weight Neonates (clinicaltrials.gov) - Sep 18, 2013
P=N/A, N=81, Completed, Sponsor: Mount Sinai School of Medicine
N=50 --> 81 Recruiting --> Completed
- | Cabometyx (cabozantinib tablet) / Exelixis, Ipsen
Trial completion: A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors (clinicaltrials.gov) - Sep 16, 2013
P1, N=40, Completed, Sponsor: Exelixis
Recruiting --> Completed Active, not recruiting --> Completed
- Biomarker, Enrollment change: Molecular Markers in Thyroid Cancer (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=2000, Recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed N=847 --> 2000
- Biomarker, Enrollment open: Molecular Markers in Thyroid Cancer (clinicaltrials.gov) - Sep 15, 2013
P=N/A, N=2000, Recruiting, Sponsor: OHSU Knight Cancer Institute
N=847 --> 2000 Terminated --> Recruiting
- Surgery: Acupuncture for Reduction of Inflammation (clinicaltrials.gov) - Sep 6, 2013
P=N/A, N=30, Recruiting, Sponsor: Rutgers, The State University of New Jersey
- Trial termination: Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine (clinicaltrials.gov) - Sep 3, 2013
P=N/A, N=360, Terminated, Sponsor: National Cancer Institute (NCI)
Terminated --> Recruiting Completed --> Terminated
- Trial completion: Near Infrared Fluorescent Imaging in Thyroid and Parathyroid Surgery With the Fluobeam(TM) System of Fluoptics (clinicaltrials.gov) - Aug 22, 2013
P1, N=10, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Completed --> Terminated Recruiting --> Completed
- MRI: Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study (clinicaltrials.gov) - Aug 21, 2013
P=N/A, N=20, Recruiting, Sponsor: Massachusetts General Hospital
- Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
New P4 trial: The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (clinicaltrials.gov) - Aug 20, 2013
P4, N=30, Not yet recruiting, Sponsor: Stanford University
- Iclusig (ponatinib) / Takeda
Enrollment open: Ponatinib for Advanced Medullary Thyroid Cancer (clinicaltrials.gov) - Aug 20, 2013
P2, N=31, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Not yet recruiting --> Recruiting
- MIKA Diclofenac Spray Gel (diclofenac spraygel) / Nogra Pharma
Enrollment change: Adjuvant Treatment of Graves (clinicaltrials.gov) - Aug 19, 2013
P4, N=65, Active, not recruiting, Sponsor: Mikael Lantz
Not yet recruiting --> Recruiting N=150 --> 65
- MIKA Diclofenac Spray Gel (diclofenac spraygel) / Nogra Pharma
Enrollment closed: Adjuvant Treatment of Graves (clinicaltrials.gov) - Aug 19, 2013
P4, N=65, Active, not recruiting, Sponsor: Mikael Lantz
N=150 --> 65 Recruiting --> Active, not recruiting
- | dacarbazine / Generic mfg., imatinib / Generic mfg., capecitabine / Generic mfg.
Enrollment change, Combination therapy: Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma (clinicaltrials.gov) - Aug 15, 2013
P1/2, N=21, Completed, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting N=52 --> 21
- | dacarbazine / Generic mfg., imatinib / Generic mfg., capecitabine / Generic mfg.
Trial completion, Combination therapy: Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma (clinicaltrials.gov) - Aug 15, 2013
P1/2, N=21, Completed, Sponsor: M.D. Anderson Cancer Center
N=52 --> 21 Active, not recruiting --> Completed